One million exomes identify FNIP1 as a metabolic brake.

Nobuyuki Enzan, Satoshi Koyama

Abstract read

In one paragraph

Article in Trends in genetics : TIG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nobuyuki EnzanCardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, MA, USA; Heart and Vascular Institute, Mass General Brigham, Boston, MA, USA.

Satoshi KoyamaCardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, MA, USA; Heart and Vascular Institute, Mass General Brigham, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Personalized Medicine, Mass General Brigham, Cambridge, MA, USA. Electronic address: skoyama2@mgh.harvard.edu.

Funding

Whole genome sequence interpretation for lipids to discover new genes and mechanisms for coronary artery diseaseR00HL169733 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI Satoshi Koyama · 2026 to 2026

$249k

NHLBI NIH HHS R00 HL169733

6 · The paper itself

Abstract

Exome sequencing of more than 1 million people uncovered dozens of genes linked to the biomarker of the body's energy state (Hindy et al.). Rare loss-of-function variants in FNIP1, a suppressor of mitochondrial energy expenditure, were associated with lower cardiometabolic disease risk, nominating selective FNIP1 inhibition as a therapeutic strategy.

Indexed as

cardiometabolic diseasedrug target discoveryenergy metabolismexome sequencingFNIP1rare variants

Identifiers

PMID42791079

DOI10.1016/j.tig.2026.09.003

PMCPMC13618734

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.